Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

AGIOS PHARMACEUTICALS, INC.

AGIO · Nasdaq · CIK 0001439222 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

0 qualifying P purchase groups
in the current 180-day scoring window

14 Form 4 transaction lines observed in the same window
2 sales · 12 option, withholding, award, gift or other lines

Last qualifying purchaseNo qualifying purchase is present in the local Form 4 history.

WHY NO ACTIVE SIGNAL?

Purchase activityNone
Recent buyingNone
Recent salesLow
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Gheuens SarahChief Medical Officer
○▼▼
CAPELLO JEFFREY DDirector
○○
Owen Adams CatherineDirector
○○
Ballal Rahul D.Director
○
Foster-Cheek Kaye IDirector
○
FOUSE JACQUALYN ADirector
○
● Purchase▼ Sale○ Other

Showing the six most active owners; 4 additional owner(s) remain in Form 4 evidence.

Purchase breadth, concentration & cluster buying

These modules activate when qualifying purchases enter the 180-day research window.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot.—

Recent Form 4 activity

0Purchases
39Sales
48Other Form 4 lines
37SEC filings · 365 days
BUYING0 qualifying P line(s) · 180 days
SELLING2 sale line(s) · context only
OTHER12 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-4.2%
3M
-25.8%
6M
-9.7%
12M
-21.7%

Volatility & liquidity

Volatility
66.0%
Beta
0.63
Avg daily value
USD 34.1M

Valuation

Market cap
USD 1.9B
P/E
—

Fundamentals

Profit margin
-764.4%
ROE
-34.6%
Industry
Biotechnology

Market data

Price data up to: 2026-10-06 · Price source: OpenBB/yfinance · From SEC filings: Profit margin, ROE · Fiscal year ended: 2025-12-31 · From Yahoo Finance: Market cap · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
7,016,166
Previous report
7,557,252
Avg daily volume
1,089,910
Days to cover
6.4

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

No qualifying code P equity purchase is present in the local Form 4 history.

Form 4 evidence

87 transaction lines in the latest 365-day window; 496 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-04Gheuens SarahSale (S)Common stock30,000USD 30.48USD 914,400SEC filing ↗
2026-07-08Backstrom Jay T.Award / grant (A)Common stock1,447USD 0.00USD 0SEC filing ↗
2026-07-01Gheuens SarahSale (S)Common stock4,007USD 37.56USD 150,503SEC filing ↗
Show recent Form 4 evidence (30 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-04Gheuens SarahSale (S)Common stock30,000USD 30.48USD 914,400SEC filing ↗
2026-07-08Backstrom Jay T.Award / grant (A)Common stock1,447USD 0.00USD 0SEC filing ↗
2026-07-01Gheuens SarahSale (S)Common stock4,007USD 37.56USD 150,503SEC filing ↗
2026-07-01Gheuens SarahOption exercise / conversion (M)Common stock8,375USD 0.00USD 0SEC filing ↗
2026-06-18Smith CynthiaOption exercise / conversion (M)Common stock2,816USD 0.00USD 0SEC filing ↗
2026-06-18Scadden DavidOption exercise / conversion (M)Common stock2,816USD 0.00USD 0SEC filing ↗
2026-06-18Owen Adams CatherineOption exercise / conversion (M)Common stock2,816USD 0.00USD 0SEC filing ↗
2026-06-18Ho MaykinOption exercise / conversion (M)Common stock2,816USD 0.00USD 0SEC filing ↗
2026-06-18Foster-Cheek Kaye IOption exercise / conversion (M)Common stock2,816USD 0.00USD 0SEC filing ↗
2026-06-18FOUSE JACQUALYN AOption exercise / conversion (M)Common stock2,816USD 0.00USD 0SEC filing ↗
2026-06-18CAPELLO JEFFREY DOption exercise / conversion (M)Common stock2,816USD 0.00USD 0SEC filing ↗
2026-06-18Ballal Rahul D.Option exercise / conversion (M)Common stock2,816USD 0.00USD 0SEC filing ↗
2026-06-13Owen Adams CatherineOption exercise / conversion (M)Common stock1,976USD 0.00USD 0SEC filing ↗
2026-06-13CAPELLO JEFFREY DOption exercise / conversion (M)Common stock1,976USD 0.00USD 0SEC filing ↗
2026-04-02Viswanadhan KrishnanSale (S)Common stock2,959USD 34.71USD 102,707SEC filing ↗
2026-04-02Viswanadhan KrishnanOption exercise / conversion (M)Common stock8,100USD 0.00USD 0SEC filing ↗
2026-04-02Milanova TsvetaSale (S)Common stock3,262USD 34.71USD 113,224SEC filing ↗
2026-04-02Milanova TsvetaOption exercise / conversion (M)Common stock8,500USD 0.00USD 0SEC filing ↗
2026-04-02Jones CeciliaSale (S)Common stock3,141USD 34.71USD 109,024SEC filing ↗
2026-04-02Jones CeciliaOption exercise / conversion (M)Common stock8,500USD 0.00USD 0SEC filing ↗
2026-04-02Goff BrianSale (S)Common stock19,068USD 34.71USD 661,850SEC filing ↗
2026-04-02Goff BrianOption exercise / conversion (M)Common stock39,028USD 0.00USD 0SEC filing ↗
2026-04-02Gheuens SarahSale (S)Common stock2,940USD 34.71USD 102,047SEC filing ↗
2026-04-02Gheuens SarahOption exercise / conversion (M)Common stock8,500USD 0.00USD 0SEC filing ↗
2026-04-02Burns James WilliamSale (S)Common stock3,280USD 34.71USD 113,849SEC filing ↗
2026-04-02Burns James WilliamOption exercise / conversion (M)Common stock8,500USD 0.00USD 0SEC filing ↗
2026-03-05Viswanadhan KrishnanSale (S)Common stock2,959USD 27.80USD 82,260SEC filing ↗
2026-03-05Viswanadhan KrishnanOption exercise / conversion (M)Common stock8,100USD 0.00USD 0SEC filing ↗
2026-03-03Washburn Theodore James Jr.Sale (S)Common stock5,272USD 28.88USD 152,255SEC filing ↗
2026-03-02Washburn Theodore James Jr.Sale (S)Common stock2,223USD 28.96USD 64,378SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerAGIO
CIK0001439222
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history496 transaction lines from 2020-02-04 to 2026-08-04
0 P purchase lines · 169 S sale lines · 327 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.